# OnCo record robin-kate-kelley (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/robin-kate-kelley/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "robin-kate-kelley" ;
  schema:name "Robin Kate Kelley"@en ;
  schema:description "San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer."@en ;
  schema:url <https://onco.cc/people/robin-kate-kelley/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  onco:tag "biliary", "hcc", "immunotherapy", "trialist" ;
  schema:jobTitle "Gastrointestinal oncologist, UCSF Helen Diller Family Comprehensive Cancer Center" ;
  onco:cancers <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/hcc/> ;
  onco:institutions <https://onco.cc/institutions/ucsf/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-966-lancet-2023/> ;
  schema:affiliation <https://onco.cc/institutions/ucsf/> .